SAN

81.9

+0.05%↑

MRK1

120.45

+0.67%↑

SHL.DE

44.51

-0.65%↓

ARGX

717

-0.83%↓

FRE

48.76

+0.52%↑

SAN

81.9

+0.05%↑

MRK1

120.45

+0.67%↑

SHL.DE

44.51

-0.65%↓

ARGX

717

-0.83%↓

FRE

48.76

+0.52%↑

SAN

81.9

+0.05%↑

MRK1

120.45

+0.67%↑

SHL.DE

44.51

-0.65%↓

ARGX

717

-0.83%↓

FRE

48.76

+0.52%↑

SAN

81.9

+0.05%↑

MRK1

120.45

+0.67%↑

SHL.DE

44.51

-0.65%↓

ARGX

717

-0.83%↓

FRE

48.76

+0.52%↑

SAN

81.9

+0.05%↑

MRK1

120.45

+0.67%↑

SHL.DE

44.51

-0.65%↓

ARGX

717

-0.83%↓

FRE

48.76

+0.52%↑

Search

Fagron

Uždarymo kaina

SektoriusSveikatos priežiūra

21.3 0.71

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

21.3

Max

21.3

Pagrindiniai rodikliai

By Trading Economics

Pajamos

5.4M

46M

Pardavimai

34M

476M

P/E

Sektoriaus vid.

18.205

78.892

Dividendų pajamingumas

1.64

Pelno marža

9.569

Darbuotojai

3,989

EBITDA

16M

87M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+20.59% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

1.64%

2.38%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

114M

1.6B

Ankstesnė atidarymo kaina

20.59

Ankstesnė uždarymo kaina

21.3

Naujienos nuotaikos

By Acuity

60%

40%

322 / 374 reitingas Healthcare

Fagron Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-24 21:41; UTC

Įsigijimai, susijungimai, perėmimai

Nvidia to Buy Chip-Designer Groq for $20 Billion, CNBC Reports

2025-12-26 20:22; UTC

Rinkos pokalbiai

Oil Loses Ground On Russia-Ukraine Peace Efforts -- Market Talk

2025-12-26 20:13; UTC

Rinkos pokalbiai

U.S. Natural Gas Gains on Colder Weather Outlook -- Market Talk

2025-12-26 19:24; UTC

Įsigijimai, susijungimai, perėmimai

Nvidia's Groq Deal Is an Instagram Moment -- With 1 Big Risk -- Barrons.com

2025-12-26 17:45; UTC

Rinkos pokalbiai

U.S. Diesel Down on Lower Crude Prices, Freight-Sector Lull -- Market Talk

2025-12-26 15:52; UTC

Rinkos pokalbiai

Oil Futures Turn Lower After Steady Start -- Market Talk

2025-12-26 14:58; UTC

Rinkos pokalbiai

Silver, Gold Reach New Highs Amid Geopolitical Tension -- Market Talk

2025-12-26 14:41; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Look to End Week Higher -- Market Talk

2025-12-26 14:28; UTC

Rinkos pokalbiai

Dollar Indexes Flat as Yen Rally Wanes -- Market Talk

2025-12-26 13:47; UTC

Rinkos pokalbiai

Oil Futures Steady in Thin Holiday Trade -- Market Talk

2025-12-26 07:22; UTC

Rinkos pokalbiai

Comex Gold Futures' Strong Bullish Momentum in Play, Chart Shows -- Market Talk

2025-12-26 05:03; UTC

Rinkos pokalbiai

Malaysian Ringgit Likely to Face Pressure From Dollar Strength in 1Q -- Market Talk

2025-12-26 03:38; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-12-26 03:38; UTC

Rinkos pokalbiai

Korean Won Strengthens, Supported by Verbal Interventions -- Market Talk

2025-12-26 02:44; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-12-26 02:44; UTC

Rinkos pokalbiai

Singapore Dollar Weakens Slightly on Likely Position Adjustments -- Market Talk

2025-12-26 01:39; UTC

Rinkos pokalbiai

China's Central Bank Signals Possibility of Easing Policy in Coming Months -- Market Talk

2025-12-26 01:14; UTC

Rinkos pokalbiai

Oil Edges Higher Amid Geopolitical Tensions -- Market Talk

2025-12-26 00:34; UTC

Rinkos pokalbiai

Yen Mostly Weakens Amid Risk-on Sentiment -- Market Talk

2025-12-26 00:15; UTC

Rinkos pokalbiai

Nikkei Gains 0.6%, Led by Tech, Videogame Stocks -- Market Talk

2025-12-25 23:42; UTC

Rinkos pokalbiai

Nikkei May Trade in Range; Yen in Focus -- Market Talk

2025-12-25 23:40; UTC

Rinkos pokalbiai

Gold Edges Higher Amid Geopolitical Risks -- Market Talk

2025-12-25 00:20; UTC

Įsigijimai, susijungimai, perėmimai

Nike Climb Boosts Dow, S&P 500 -- 2nd Update

2025-12-24 22:22; UTC

Įsigijimai, susijungimai, perėmimai

Nvidia, Groq Strike AI Tech Licensing Deal -- Barrons.com

2025-12-24 21:26; UTC

Įsigijimai, susijungimai, perėmimai

Nvidia to Buy Chip-Designer Groq for $20B, CNBC Reports

2025-12-24 19:35; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-12-24 19:35; UTC

Rinkos pokalbiai

Treasury Yields Decline Ahead of Christmas -- Market Talk

2025-12-24 19:09; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Global Equities Roundup: Market Talk

2025-12-24 19:09; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

ServiceNow's Armis Acquisition Shouldn't Fuel Fears That Seat-Based Model Threatened -- Market Talk

2025-12-24 19:06; UTC

Rinkos pokalbiai

Oil Futures Little Changed in Light Pre-Holiday Trade -- Market Talk

Akcijų palyginimas

Kainos pokytis

Fagron Prognozė

Kainos tikslas

By TipRanks

20.59% į viršų

12 mėnesių prognozė

Vidutinis 19.5 EUR  20.59%

Aukščiausias 19.5 EUR

Žemiausias 19.5 EUR

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Fagron kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

1

Pirkti

0

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

322 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Fagron

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. Its products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; and SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort. In addition, the company offers education and training program to prescribers and pharmacists through the Fagron Academy. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.
help-icon Live chat